QNRX — Quoin Pharmaceuticals Ltd DRC
NASDAQ · Healthcare · Biotechnology
$6.90
+$0.39 (+5.99%)
Quoin Pharmaceuticals Ltd DRC (QNRX) is a biotechnology company listed on NASDAQ. It is led by Michael Myers Ph.D., based in 42127 Pleasant Forest Court, Ashburn, VA, United States, 20148-7349, with about 4 employees. Quoin Pharmaceuticals, Ltd., a late-stage specialty pharmaceutical company, focuses on the development and commercialization of therapeutic products for rare and orphan diseases in the United States. The company's lead product is QRX003, a topical lotion, which is in phase 2 to treat netherton syndrome (NS); phase 1 in to treat peeling skin syndrome; and in pre-clinical stage to treat SAM syndrome and ichthyosis. It also develops QRX008 for the treatment of scleroderma, which is in pre-clinical stage; and QRX009, to treat microcystic lymphatic malformations, venous malformations, angiofibroma, and other diseases. It has a research agreement with Queensland University of Technology. Quoin Pharmaceuticals, Ltd. was founded in 2018 and is based in Ashburn, Virginia. Quoin Pharmaceuticals, Ltd. is a subsidiary of Skinvisible, Inc.
Net income was -$11.5M. QNRX currently screens at market cap $9.6M.
Use this QNRX page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the QNRX quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the QNRX SEC filings page. Lician reads the product cache first so this HTML stays unique to Quoin Pharmaceuticals Ltd DRC even when a live quote feed is slow.
About Quoin Pharmaceuticals Ltd DRC
Quoin Pharmaceuticals, Ltd., a late-stage specialty pharmaceutical company, focuses on the development and commercialization of therapeutic products for rare and orphan diseases in the United States. The company's lead product is QRX003, a topical lotion, which is in phase 2 to treat netherton syndrome (NS); phase 1 in to treat peeling skin syndrome; and in pre-clinical stage to treat SAM syndrome and ichthyosis. It also develops QRX008 for the treatment of scleroderma, which is in pre-clinical stage; and QRX009, to treat microcystic lymphatic malformations, venous malformations, angiofibroma, and other diseases. It has a research agreement with Queensland University of Technology. Quoin Pharmaceuticals, Ltd. was founded in 2018 and is based in Ashburn, Virginia. Quoin Pharmaceuticals, Ltd. is a subsidiary of Skinvisible, Inc.
QNRX Key Statistics
Market Cap
$9.58M
Volume
13,037
Previous Close
$5.42
Day Range
$4.85 – $5.39
P/B Ratio
1.05
EPS
$0.00
Revenue
$0.00
Net Income
-$8.96M
Gross Profit
$0.00
Free Cash Flow
$0.00
Employees
4
QNRX Financials
Annual income statement in USD. Latest reported periods first.
| Line | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Cost of Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross Profit | $0.00 | $0.00 | $0.00 | $0.00 |
| Operating Income | $0.00 | $0.00 | $0.00 | $0.00 |
| Net Income | -$8.96M | -$8.69M | -$9.38M | -$21.46M |
| EPS (Diluted) | $0.00 | $0.00 | $0.00 | $0.00 |
Total Assets
$15.71M
Total Debt
$0.00
Shareholders' Equity
$0.00
Cash & Equivalents
$3.62M
Operating Cash Flow
-$7.86M
Free Cash Flow
$0.00
Quoin Pharmaceuticals Ltd DRC Company Information
- Co-Founder, CEO & Chairman
- Michael Myers Ph.D.
- Headquarters
- 42127 Pleasant Forest Court, Ashburn, VA, United States, 20148-7349
- Website
- quoinpharma.com
- Phone
- 703 980 4182
- IPO / Founded
- 2016-07-29
- Sector
- Healthcare
- Industry
- Biotechnology